Alnylam Pharmaceuticals
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
Sprache: Englisch
Alnylam is leading the translation of RNA interference (RNAi) into a innovative, entirely new class of medicines which we believe have the potential to transform the lives of patients who are living with rare and genetic diseases.
A Alnylam está liderando a tradução da Interferência de RNA (RNAi) em uma classe de medicamentos totalmente inovadora, que acreditamos ter o potencial de transformar a vida de pacientes acometidos por doenças genéticas e raras.
Alnylam conduit la transformation de l'interférence ARN (ARNi) en une classe de médicaments innovante, totalement nouvelle qui, selon nous, a le potentiel de transformer la vie des patients atteints d'une maladie génétique rare.
Max-Planck-Innovation ist verantwortlich für den Technologietransfer der Institute der Max-Planck-Gesellschaft, Deutschlands führender Forschungsorganisation für Grundlagenforschung.
Together we redefine healthcare by connecting the dots. Legal + strategy consulting for healthcare and life sciences.
meta home desc
Pioneering photomedicine & PhotoCosmetics
SAE Media Group is a highly professional, global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. Part of the SAE Media Group, SMi researches, creates and delivers events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.
Das Gesundheitswesen und die Wissenschaft aus Bürger- und Patientensicht. Der Blog behandelt die Themen Interessenkonflikte, Transparenz, Patientenorganisationen, evidenzbasierte Medizin und Pharma.
Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.
ISA Pharmaceuticals develops targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.